Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Table 2

Comparison of pre- and postintervention kidney function and contrast-induced acute renal injury between those who received evolocumab and controls.

	Control group (n = 160)	Evolocumab group (n = 149)	χ^2/t/Z	value
Pre-PCI Cr (μmol/L), median (IQR)	78.00 (67.00–89.00)	78.00 (65.00–87.5)	−0.96	0.34
Post-PCI Cr (μmol/L), median (IQR)	86.00 (73.00–99.00)	80.00 (69.00–90.00)	−3.69	<0.01
Cr change pre- to post-PCI (%), median (IQR)	7.14 (1.12–20.26)	3.45 (−1.18–12.79)	−3.28	<0.01
CI-AKI, n (%)	32 (20.00)	10 (6.70)	11.60	<0.01

χ²/t/Z, a test used to compare parameters. IQR, interquartile range; PCI, percutaneous coronary intervention; Cr, creatinine; CI-AKI, contrast-induced acute renal injury.